View Document Preview and Link Document Date: 2014-10-17 10:50:06 Open Document File Size: 1,06 MB Share Result on Facebook
City Reference / / Company Genentech / / Event FDA Phase / / Facility National Cancer Institute of Canada Common Toxicity Criteria / National Cancer Institute of Canada / / IndustryTerm treatment of Dukes’ C colon cancer / therapy for metastatic colorectal cancer / treatment of patients with metastatic breast cancer / treatment of metastatic breast cancer / therapy for Dukes’ C colon cancer / / MedicalCondition Steven-Johnson Syndrome / abdominal pain / tumor / Necrotizing enterocolitis / liver metastases / dysesthesia / cancer / cardiomyopathy / colorectal carcinoma / disease / Colorectal Cancer / Dihydropyrimidine Dehydrogenase Deficiency / cardiac failure / Carcinogenesis / dysfunction / neutropenia / nausea / C colon cancer / stomatitis / thrombocytopenia / Metastatic Colorectal Cancer / Toxic Epidermal Necrolysis / erythema / correct dehydration / hepatic metastases / Stevens-Johnson syndrome / typhlitis / vomiting / numbness / Adjuvant Colon Cancer / fatigue / Metastatic Breast Cancer / myocardial infarction / coronary artery disease / granulocytopenia / Hypersensitivity / Diarrhea / angina / cardiac arrest / deficiency / Renal Failure / hand-and-foot syndrome / metastases / Breast Cancer / paresthesia / anemia / acute renal failure / syndrome / Dehydrogenase (DPD) Deficiency / Hepatic Insufficiency / Dehydration / / MedicalTreatment combination chemotherapy / chemotherapy / adjuvant therapy / / Organization DOSAGE AND ADMINISTRATION / FDA / / / Position physician / General / / Product Phenytoin / paclitaxel / XELODA / fluorouracil / / Technology Geriatrics / Pharmacokinetics / chemotherapy / / URL www.fda.gov/medwatch / / SocialTag 
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XELODA safely and effectively. See full prescribing information for XELODA. ------------------------------ CO